Results 271 to 280 of about 15,083 (304)
Some of the next articles are maybe not open access.
Vigabatrin for Infantile Spasms
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011Infantile spasms describe a pediatric epilepsy syndrome characterized by frequent clusters of brief symmetric muscle contractions; the condition is often associated with developmental delay. When infantile spasms are accompanied by hypsarrhythmia on electroencephalogram, the condition is labeled West syndrome.
Kimberly A. Pesaturo +2 more
openaire +2 more sources
The Neuropathology of Vigabatrin
Epilepsia, 1989Summary: Vigabatrin (gamma vinyl GABA, GVG), an enzyme‐activated, irreversible inhibitor of GABA transaminase, was administered orally to rats, dogs, and monkeys to observe toxicologic reactions. Myelin vacuolation of the brain was observed. The vacuolation was limited to myelinated tracts and resulted from separation of the myelin sheath at the ...
openaire +3 more sources
Vigabatrin and behaviour disturbances
The Lancet, 1990We have been using vigabatrin in clinical trials and on a named-patient basis on compassionate grounds for the past three years. We have treated 145 patients who had intractable seizure disorders, with varying degrees of success: 47% showed a definite improvement in seizure control. 44 patients experienced side-effects, most of these occurring early in
Josemir W. Sander, Y. M. Hart
openaire +3 more sources
Vigabatrin in Childhood Epilepsy
Journal of Child Neurology, 1991Sixty-six children with various types of severe drug-resistant epilepsy were entered into a long-term, dose-rising study of vigabatrin after a 4-week run-in placebo period. All the children were receiving one to three other antiepileptic drugs, the doses of which were not changed during the 6-month dose titration phase.
Daniel Beaumont +6 more
openaire +3 more sources
Vigabatrin treatment in children
Child's Nervous System, 1994Sixty-nine children, aged from 2 months to 16 years and suffering from different types of drug-resistant epileptic seizures, mostly complex partial and secondary generalised, were recruited in an open, uncontrolled, prospective study of treatment with vigabatrin (gamma-vinyl GABA).
FOIS, A. +4 more
openaire +4 more sources
Vigabatrin for refractory partial epilepsy
Cochrane Database of Systematic Reviews, 2008Epilepsy is a common neurological condition which affects between 0.5% and 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs, and the majority of these people have partial epilepsy. Vigabatrin is an antiepileptic drug licensed for use in the treatment of refractory epilepsy.
Melissa J Maguire +3 more
openaire +4 more sources
Examining the role of vigabatrin
Neurology, 1996Until vigabatrin (Sabril) was introduced in the United Kingdom in 1990 and, more recently, came into use in other parts of the world, clinicians had no new antiepileptic drugs (AEDs) at their disposal for 20 years. Although vigabatrin remains investigational in the United States, Food and Drug Administration approval is likely in the near future.
openaire +3 more sources
Vigabatrin for Epileptic Spasms and Tonic Seizures in Tuberous Sclerosis Complex
Journal of Child Neurology, 2018Emma A van der Poest Clement +2 more
semanticscholar +1 more source